Clinical Trial Update: Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial of Exenatide-LAR combined with dapagliflozin in overweight/obese patients with Type 2 diabetes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• Exenatide-LAR (exenatide)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: WITHDRAWN